A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC 703813, IND70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Trial Profile

A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC 703813, IND70116) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms Alliance; CALGB 50803
  • Most Recent Events

    • 24 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2017 Primary endpoint (Number of Participants Who Achieved a Complete Response) has been met, according to the results published in the Annals of Oncology
    • 31 Aug 2017 Results published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top